Essex Property Trust, Inc. vs Heron Therapeutics Inc — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.20B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Essex Property Trust, Inc. is far larger — about 287× Heron Therapeutics Inc's market cap, and Essex Property Trust, Inc. pays a 3.66% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ESS | HRTX | |
|---|---|---|
Market Cap | $18.20B | $63.41M |
Sector | Real Estate | Health |
52-Week High | $298.33 | $1.49 |
52-Week Low | $239.61 | $0.33 |
Enterprise Value | $24.80B | $161.31M |
Dividend Yield | 3.66% | — |
Signals from Pluang's Aura AI — not financial advice
ESS trades at $288.1, up 1.05% daily, with a neutral technical signal and support near $284. The stock shows strong profitability with a 21.48% net margin and recent Q2 2026 earnings miss on EPS but beat on FFO, leading to raised full-year guidance. Revenue growth is steady, reaching $1.89B in 2025, though net income declined to $670M from $742M in 2024.
Outlook is cautiously optimistic with a consensus price target of $305.86, implying ~6% upside. Risks include high debt levels (debt-to-asset ratio of 51.92% in 2024) and regional economic exposure. Analyst sentiment is mixed with 40% buy ratings, but institutional interest grew with Amundi increasing its stake in Q1 2026.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →